Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL

被引：8

作者：

Bachy, Emmanuel ^{[1
,2
]}

Salles, Gilles ^{[1
,2
,3
]}

机构：

[1] Hosp Civils Lyon, F-69495 Pierre Benite, France

[2] Univ Lyon 1, F-69495 Pierre Benite, France

[3] CNRS, UMR 5239, Lyon, France

来源：

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2011年 / 24卷 / 02期

关键词：

follicular lymphoma; autologous stem cell transplantation; rituximab; late toxicity; conditioning regimen; HIGH-DOSE THERAPY; NON-HODGKINS-LYMPHOMA; IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY; ACUTE MYELOGENOUS LEUKEMIA; TERM-FOLLOW-UP; SECONDARY MYELODYSPLASTIC SYNDROME; PROGRESSION-FREE SURVIVAL; ACUTE MYELOID-LEUKEMIA; REFRACTORY LOW-GRADE; BONE-MARROW;

D O I：

10.1016/j.beha.2011.03.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

High-dose therapy followed by autologous stem cell transplantation is widely accepted as salvage therapy for patients with relapsed aggressive lymphoma. In the pre-rituximab era, autologous stem cell transplantation had also been increasingly applied as a consolidation treatment for patients with indolent lymphoma in second or subsequent remission whereas controversies have emerged concerning its role in first line therapy from several randomized trials. Broad development and amazing efficacy of monoclonal antibody-based combination therapies for de novo or relapsing follicular lymphoma patients render previous conclusions outdated and underline the critical need for further phase III trials. This review focuses on available data from pre-rituximab and rituximab eras to help clarifying the precise role and timing of autologous stem cell transplantation among the current armamentarium for follicular lymphoma treatment. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：257 / 270

页数：14

共 70 条

[31] Pivotal study of iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas [J].

Kaminski, MS ;

Zelenetz, AD ;

Press, OW ;

Saleh, M ;

Leonard, J ;

Fehrenbacher, L ;

Lister, TA ;

Stagg, RJ ;

Tidmarsh, GF ;

Kroll, S ;

Wahl, RL ;

Knox, SJ ;

Vose, JM .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (19) :3918-3928

[32] The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation [J].

Keeney, Grant E. ;

Gooley, Ted A. ;

Pham, Rosalyn N. ;

Press, Oliver W. ;

Pagel, John M. ;

Petersdorf, Stephen H. ;

Maloney, David G. ;

Bensinger, William ;

Holmberg, Leona ;

Gopal, Ajay K. .

LEUKEMIA & LYMPHOMA, 2007, 48 (10) :1961-1967

[33] Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors [J].

Krishnan, A ;

Bhatia, S ;

Slovak, ML ;

Arber, DA ;

Niland, JC ;

Nademanee, A ;

Fung, H ;

Bhatia, R ;

Kashyap, A ;

Molina, A ;

O'Donnell, MR ;

Parker, PA ;

Sniecinski, I ;

Snyder, DS ;

Spielberger, R ;

Stein, A ;

Forman, SJ .

BLOOD, 2000, 95 (05) :1588-1593

[34] Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma [J].

Krishnan, Amrita ;

Nademanee, Auayporn ;

Fung, Henry C. ;

Raubitschek, Andrew A. ;

Molina, Arturo ;

Yamauchi, Dave ;

Rodriguez, Roberto ;

Spielberger, Ricardo T. ;

Falk, Peter ;

Palmer, Joycelynne M. ;

Forman, Stephen J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (01) :90-95

[35] Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage [J].

Ladetto, Marco ;

De Marco, Federica ;

Benedetti, Fabio ;

Vitolo, Umberto ;

Patti, Caterina ;

Rambaldi, Alessandro ;

Pulsoni, Alessandro ;

Musso, Maurizio ;

Liberati, Anna M. ;

Olivieri, Attilio ;

Gallamini, Andrea ;

Pogliani, Enrico ;

Scalabrini, Delia Rota ;

Callea, Vincenzo ;

Di Raimondo, Francesco ;

Pavone, Vincenzo ;

Tucci, Alessandra ;

Cortelazzo, Sergio ;

Levis, Alessandro ;

Boccadoro, Mario ;

Majolino, Ignazio ;

Pileri, Alessandro ;

Gianni, Alessandro M. ;

Passera, Roberto ;

Corradini, Paolo ;

Tarella, Corrado .

BLOOD, 2008, 111 (08) :4004-4013

[36]

Le Dortz L, 2010, EUR J NUCL MED 0818

[37]

Le Gouill S, 2008, BLOOD, V112

[38] Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group [J].

Lenz, G ;

Dreyling, M ;

Schiegnitz, E ;

Haferlach, T ;

Hasford, J ;

Unterhalt, M ;

Hiddemann, W .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (24) :4926-4933

[39] Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group [J].

Lenz, G ;

Dreyling, M ;

Schiegnitz, E ;

Forstpointner, R ;

Wandt, H ;

Freund, M ;

Hess, G ;

Truemper, L ;

Diehl, V ;

Kropff, M ;

Kneba, M ;

Schmitz, N ;

Metzner, B ;

Pfirrmann, M ;

Unterhalt, M ;

Hiddemann, W .

BLOOD, 2004, 104 (09) :2667-2674

[40] Improved survival for patients with follicular lymphoma [J].

Lister, TA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :4830-4831

← 1 2 3 4 5 6 7 →